RVL Pharmaceuticals, Inc.

RVL Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes eyecare and medical-aesthetics products for underserved patient populations. Its flagship product, Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%), is an FDA-approved, nonsurgical treatment for acquired blepharoptosis, or low-lying eyelids in adults. The company also offers skincare products and combines pioneering products with technology-enabled access and integrated fulfillment for consumers and healthcare providers.